These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21848318)

  • 1. Assessing atropisomer axial chirality in drug discovery and development.
    Laplante SR; D Fader L; Fandrick KR; Fandrick DR; Hucke O; Kemper R; Miller SP; Edwards PJ
    J Med Chem; 2011 Oct; 54(20):7005-22. PubMed ID: 21848318
    [No Abstract]   [Full Text] [Related]  

  • 2. Mitigating heterocycle metabolism in drug discovery.
    St Jean DJ; Fotsch C
    J Med Chem; 2012 Jul; 55(13):6002-20. PubMed ID: 22533875
    [No Abstract]   [Full Text] [Related]  

  • 3. Assembly of hybrid synthetic capsules.
    Ajami D; Schramm MP; Volonterio A; Rebek J
    Angew Chem Int Ed Engl; 2007; 46(1-2):242-4. PubMed ID: 17146821
    [No Abstract]   [Full Text] [Related]  

  • 4. Stereoselective synthesis of the diazonamide a macrocyclic core.
    Mutule I; Joo B; Medne Z; Kalnins T; Vedejs E; Suna E
    J Org Chem; 2015 Mar; 80(6):3058-66. PubMed ID: 25705925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revealing atropisomer axial chirality in drug discovery.
    LaPlante SR; Edwards PJ; Fader LD; Jakalian A; Hucke O
    ChemMedChem; 2011 Mar; 6(3):505-13. PubMed ID: 21360821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atropisomerism in medicinal chemistry: challenges and opportunities.
    Toenjes ST; Gustafson JL
    Future Med Chem; 2018 Feb; 10(4):409-422. PubMed ID: 29380622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Chen KX; Bogen S; Nair L; Tong X; Chase R; Hart A; Agrawal S; Pichardo J; Prongay A; Cheng KC; Girijavallabhan V; Piwinski J; Shih NY; Njoroge FG
    J Med Chem; 2009 Jan; 52(2):336-46. PubMed ID: 19102654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atropselective syntheses of (-) and (+) rugulotrosin A utilizing point-to-axial chirality transfer.
    Qin T; Skraba-Joiner SL; Khalil ZG; Johnson RP; Capon RJ; Porco JA
    Nat Chem; 2015 Mar; 7(3):234-40. PubMed ID: 25698333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fused tetracycles with a benzene or cyclohexadiene core: [2 + 2 + 2] cycloadditions on macrocyclic systems.
    Brun S; Garcia L; González I; Torrent A; Dachs A; Pla-Quintana A; Parella T; Roglans A
    Chem Commun (Camb); 2008 Sep; (36):4339-41. PubMed ID: 18802563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient formal total synthesis of the erythrina alkaloid (+)-erysotramidine, using a domino process.
    Tietze LF; Tölle N; Kratzert D; Stalke D
    Org Lett; 2009 Nov; 11(22):5230-3. PubMed ID: 19860384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
    Doak BC; Over B; Giordanetto F; Kihlberg J
    Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs-miracles or mirages?
    JAMA; 2014 Jan 22-29; 311(4):423. PubMed ID: 24449329
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and registration of chiral drugs.
    Witte DT; Ensing K; Franke JP; De Zeeuw RA
    Pharm World Sci; 1993 Feb; 15(1):10-6. PubMed ID: 8485501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
    Ishikawa M; Hashimoto Y
    J Med Chem; 2011 Mar; 54(6):1539-54. PubMed ID: 21344906
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthesis of the tetracyclic core of the tetrapetalones through transannular oxidative [4+3] cyclization.
    Wang X; Porco JA
    Angew Chem Int Ed Engl; 2005 May; 44(20):3067-71. PubMed ID: 15832389
    [No Abstract]   [Full Text] [Related]  

  • 16. The total synthesis of (+/-)-fortucine and a revision of the structure of kirkine.
    Biechy A; Hachisu S; Quiclet-Sire B; Ricard L; Zard SZ
    Angew Chem Int Ed Engl; 2008; 47(8):1436-8. PubMed ID: 18200639
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ligand efficiency and lead optimization].
    Guo ZR
    Yao Xue Xue Bao; 2013 Dec; 48(12):1755-62. PubMed ID: 24689231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A timely re-examination of drug polymorphism in pharmaceutical development and regulation.
    Grant DJ; Byrn SR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):237-9. PubMed ID: 14962580
    [No Abstract]   [Full Text] [Related]  

  • 19. Has the FDA Amendments Act of 2007 impaired drug development?
    Franson TR
    Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?
    Giordanetto F; Kihlberg J
    J Med Chem; 2014 Jan; 57(2):278-95. PubMed ID: 24044773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.